Compare FuelCell Energy Inc (FCEL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Sanofi SA — how do they compare? FuelCell Energy Inc trades at $17.66 (market cap $1.47B), while Sanofi SA trades at $40.2 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 65.9× FuelCell Energy Inc's market cap, and Sanofi SA pays a 6.02% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Sanofi SA for 94 Days on average.
| FCEL | SNY | |
|---|---|---|
Market Cap | $1.47B | $96.81B |
Volume | 12,559,948 | 2,081,815 |
Sector | Industrials | Health |
52-Week High | $36.01 | $52.34 |
52-Week Low | $6.00 | $39.51 |
Typical Hold Time | 48 Days | 94 Days |
Enterprise Value | $1.05B | $116.20B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.245, down 16.49% over 24 hours, reflecting recent volatility amid a securities class action. The stock shows a bullish technical signal with support near $17 and resistance at $19. Fundamentally, the company reported revenue of $158.16 million for 2025 but posted a net loss of $187.90 million, with negative profit margins persisting. Cash flow improved in 2025 with net cash flow of $132.91 million, though operational cash flow remains negative.
The outlook is cautious; while analyst consensus suggests a $21.57 price target with 40% buy ratings, ongoing legal challenges and consistent losses pose significant risks. Investment opportunity hinges on execution turnaround and market adoption of hydrogen energy, but high volatility and financial instability warrant careful consideration.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
